pslik idh2 flag Search Results


lentiviral plasmids pslik idh2 flag  (Addgene inc)
90
Addgene inc lentiviral plasmids pslik idh2 flag
MISTRG replicate granulocytic and megakaryocytic differentiation in response to inhibition of mutant <t>IDH2.</t> In vivo treatment of mutant <t>IDH2</t> R140Q in MDS-EB-2 (Y021) engrafted MISTRG mice with the IDH2 MUT inhibitor enasidenib. ( a ) Representative histologic images of vehicle (n=8, left) and enasidenib (n=6, right) treated mice engrafted with MDS-EB-2 (Y021). IHC stains for huCD45, huCD68, huCD15, and huCD61 (scale bars 10μm, original magnification 60X). ( b ) Representative FACS plots showing myeloid maturation in response to enasidenib and quantitation of huCD15+ and huCD11b+ expression in vehicle versus enasidenib treated MISTRG mice. ( c ) Comparison of human engraftment in BM from vehicle (n=8) and enasidenib (n=6) treated MISTRG mice. ( d ) Quantitation of huCD41+ expression in PB and BM from vehicle (n=8) and enasidenib (n=6) treated MISTRG mice ( e ) Quantitation of D-2HG in plasma of pre- and post-administration of Vehicle or Enasidenib. Individual mice are represented by symbols with mean ± S.E.M.; statistics represent Mann Whitney test; n.s. not significant, *p<0.05, **p<0.01 for aggregate NSG vs. MISTRG. ( f ) Representation of VAFs of driver mutations in vehicle (left) or enasidenib (right) treated MISTRG (y-axis) plotted against the patient’s VAFs (x-axis). Individual mice represented by symbol shape, mutations color coded. Linear regressors, pearson correlations and p-values between patient and xenograft VAF are displayed.
Lentiviral Plasmids Pslik Idh2 Flag, supplied by Addgene inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/lentiviral plasmids pslik idh2 flag/product/Addgene inc
Average 90 stars, based on 1 article reviews
lentiviral plasmids pslik idh2 flag - by Bioz Stars, 2025-04
90/100 stars
  Buy from Supplier
idh2 r172k flag cdna  (Addgene inc)
90
Addgene inc idh2 r172k flag cdna
MISTRG replicate granulocytic and megakaryocytic differentiation in response to inhibition of mutant <t>IDH2.</t> In vivo treatment of mutant <t>IDH2</t> R140Q in MDS-EB-2 (Y021) engrafted MISTRG mice with the IDH2 MUT inhibitor enasidenib. ( a ) Representative histologic images of vehicle (n=8, left) and enasidenib (n=6, right) treated mice engrafted with MDS-EB-2 (Y021). IHC stains for huCD45, huCD68, huCD15, and huCD61 (scale bars 10μm, original magnification 60X). ( b ) Representative FACS plots showing myeloid maturation in response to enasidenib and quantitation of huCD15+ and huCD11b+ expression in vehicle versus enasidenib treated MISTRG mice. ( c ) Comparison of human engraftment in BM from vehicle (n=8) and enasidenib (n=6) treated MISTRG mice. ( d ) Quantitation of huCD41+ expression in PB and BM from vehicle (n=8) and enasidenib (n=6) treated MISTRG mice ( e ) Quantitation of D-2HG in plasma of pre- and post-administration of Vehicle or Enasidenib. Individual mice are represented by symbols with mean ± S.E.M.; statistics represent Mann Whitney test; n.s. not significant, *p<0.05, **p<0.01 for aggregate NSG vs. MISTRG. ( f ) Representation of VAFs of driver mutations in vehicle (left) or enasidenib (right) treated MISTRG (y-axis) plotted against the patient’s VAFs (x-axis). Individual mice represented by symbol shape, mutations color coded. Linear regressors, pearson correlations and p-values between patient and xenograft VAF are displayed.
Idh2 R172k Flag Cdna, supplied by Addgene inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/idh2 r172k flag cdna/product/Addgene inc
Average 90 stars, based on 1 article reviews
idh2 r172k flag cdna - by Bioz Stars, 2025-04
90/100 stars
  Buy from Supplier

Image Search Results


MISTRG replicate granulocytic and megakaryocytic differentiation in response to inhibition of mutant IDH2. In vivo treatment of mutant IDH2 R140Q in MDS-EB-2 (Y021) engrafted MISTRG mice with the IDH2 MUT inhibitor enasidenib. ( a ) Representative histologic images of vehicle (n=8, left) and enasidenib (n=6, right) treated mice engrafted with MDS-EB-2 (Y021). IHC stains for huCD45, huCD68, huCD15, and huCD61 (scale bars 10μm, original magnification 60X). ( b ) Representative FACS plots showing myeloid maturation in response to enasidenib and quantitation of huCD15+ and huCD11b+ expression in vehicle versus enasidenib treated MISTRG mice. ( c ) Comparison of human engraftment in BM from vehicle (n=8) and enasidenib (n=6) treated MISTRG mice. ( d ) Quantitation of huCD41+ expression in PB and BM from vehicle (n=8) and enasidenib (n=6) treated MISTRG mice ( e ) Quantitation of D-2HG in plasma of pre- and post-administration of Vehicle or Enasidenib. Individual mice are represented by symbols with mean ± S.E.M.; statistics represent Mann Whitney test; n.s. not significant, *p<0.05, **p<0.01 for aggregate NSG vs. MISTRG. ( f ) Representation of VAFs of driver mutations in vehicle (left) or enasidenib (right) treated MISTRG (y-axis) plotted against the patient’s VAFs (x-axis). Individual mice represented by symbol shape, mutations color coded. Linear regressors, pearson correlations and p-values between patient and xenograft VAF are displayed.

Journal: bioRxiv

Article Title: A Highly Efficient and Faithful MDS Patient-Derived Xenotransplantation Model for Pre-Clinical Studies

doi: 10.1101/265082

Figure Lengend Snippet: MISTRG replicate granulocytic and megakaryocytic differentiation in response to inhibition of mutant IDH2. In vivo treatment of mutant IDH2 R140Q in MDS-EB-2 (Y021) engrafted MISTRG mice with the IDH2 MUT inhibitor enasidenib. ( a ) Representative histologic images of vehicle (n=8, left) and enasidenib (n=6, right) treated mice engrafted with MDS-EB-2 (Y021). IHC stains for huCD45, huCD68, huCD15, and huCD61 (scale bars 10μm, original magnification 60X). ( b ) Representative FACS plots showing myeloid maturation in response to enasidenib and quantitation of huCD15+ and huCD11b+ expression in vehicle versus enasidenib treated MISTRG mice. ( c ) Comparison of human engraftment in BM from vehicle (n=8) and enasidenib (n=6) treated MISTRG mice. ( d ) Quantitation of huCD41+ expression in PB and BM from vehicle (n=8) and enasidenib (n=6) treated MISTRG mice ( e ) Quantitation of D-2HG in plasma of pre- and post-administration of Vehicle or Enasidenib. Individual mice are represented by symbols with mean ± S.E.M.; statistics represent Mann Whitney test; n.s. not significant, *p<0.05, **p<0.01 for aggregate NSG vs. MISTRG. ( f ) Representation of VAFs of driver mutations in vehicle (left) or enasidenib (right) treated MISTRG (y-axis) plotted against the patient’s VAFs (x-axis). Individual mice represented by symbol shape, mutations color coded. Linear regressors, pearson correlations and p-values between patient and xenograft VAF are displayed.

Article Snippet: To generate isogenic wildtype and mutant expressing cell lines the lentiviral plasmids pSLIK-IDH2-FLAG and pSLIK-IDH2-R172K-FLAG (a gift from Christian Metallo, Addgene plasmid ## 66806, 6680, ) were used to transduce human erythroid leukemia cell (HEL) cell lines.

Techniques: Inhibition, Mutagenesis, In Vivo, Quantitation Assay, Expressing, MANN-WHITNEY